X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-20

Reporting Person: SVLSF V, LLC (10% Owner)
Reporting Person: SV Life Sciences Fund VI Strategic Partners, L.P. (10% Owner)
Reporting Person: SV Life Sciences Fund VI, L.P. (10% Owner)
Reporting Person: SV Life Sciences Fund V Strategic Partners, L.P. (10% Owner)
Reporting Person: SV LIFE SCIENCES FUND V LP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-20	Common Stock	C	19128	—	Acquired	19128	Direct
2017-11-20	Common Stock	C	404	—	Acquired	19532	Direct
2017-11-20	Common Stock	C	247010	—	Acquired	266542	Direct
2017-11-20	Common Stock	C	5219	—	Acquired	271761	Direct
2017-11-20	Common Stock	C	322102	—	Acquired	593863	Direct
2017-11-20	Common Stock	C	6806	—	Acquired	600669	Direct
2017-11-20	Common Stock	C	111955	—	Acquired	712624	Direct
2017-11-20	Common Stock	C	2365	—	Acquired	714989	Direct
2017-11-20	Common Stock	C	202915	—	Acquired	917904	Direct
2017-11-20	Common Stock	C	4288	—	Acquired	922192	Direct
2017-11-20	Common Stock	C	431980	—	Acquired	1354172	Direct
2017-11-20	Common Stock	C	14789	—	Acquired	1368961	Direct
2017-11-20	Common Stock	P	483448	$10.00	Acquired	1852409	Direct
2017-11-20	Common Stock	P	16552	$10.00	Acquired	1868961	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-20	Series A-1 Convertible Preferred Stock	$	C	65287	Disposed		Common Stock (19128)	Direct
2017-11-20	Series A-1 Convertible Preferred Stock	$	C	1380	Disposed		Common Stock (404)	Direct
2017-11-20	Series A-2 Convertible Preferred Stock	$	C	690259	Disposed		Common Stock (247010)	Direct
2017-11-20	Series A-2 Convertible Preferred Stock	$	C	14587	Disposed		Common Stock (5219)	Direct
2017-11-20	Series B Convertible Preferred Stock	$	C	721402	Disposed		Common Stock (322102)	Direct
2017-11-20	Series B Convertible Preferred Stock	$	C	15246	Disposed		Common Stock (6806)	Direct
2017-11-20	Series C Convertible Preferred Stock	$	C	224665	Disposed		Common Stock (111955)	Direct
2017-11-20	Series C Convertible Preferred Stock	$	C	4747	Disposed		Common Stock (2365)	Direct
2017-11-20	Series D Convertible Preferred Stock	$	C	692552	Disposed		Common Stock (202915)	Direct
2017-11-20	Series D Convertible Preferred Stock	$	C	14635	Disposed		Common Stock (4288)	Direct
2017-11-20	Series D Convertible Preferred Stock	$	C	1474348	Disposed		Common Stock (431980)	Direct
2017-11-20	Series D Convertible Preferred Stock	$	C	50477	Disposed		Common Stock (14789)	Direct

Footnotes

F1: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F2: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F3: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F4: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F5: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F6: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F7: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F8: These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F9: These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.